The Lynx Group

Axitinib Promising Second-Line Treatment for Advanced Renal Carcinoma

December 2011, Vol 2, No 7

This is the first phase 3 clinical trial to compare the effectiveness of 2 second- generation antiangiogenic agents —axitinib and sorafenib—for meta - static renal-cell cancer, showing great promise for the investigational drug axitinib (Rini BI, et al. Lancet. 2011;378: 1931-1939).

This randomized trial included 723 patients (from 175 sites in 22 countries) with renal-cell carcinoma that had progressed despite the use of first-line therapy with sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were randomized to axitinib 5 mg initially and titrated up to 10 mg twice daily (N = 361) or to sorafenib 400 mg twice daily (N = 362).

The primary end point was progression- free survival (PFS). Secondary end points were overall survival (OS), objective response rate, response duration, and time to deterioration.

The median PFS was significantly (42%) longer with axitinib (6.7 months) than with sorafenib (4.7 months). In those who had previously received cytokines, the median PFS was 12.1 months with axitinib compared with 6.5 months sorafenib; in those who had previously received sunitinib it was 4.8 months versus 3.4 months, respectively.

The objective response rate was 19% with axitinib versus 9% with sorafenib. A total of 14 (4%) of the 359 patients who received axitinib and 29 (8%) of the 355 patients who received sorafenib discontinued treatment because of adverse effects. The most common adverse events reported were diarrhea, hypertension, and fatigue in the axitinib group and diarrhea, palmar- plantar erythrodysesthesia, and alopecia in the sorafenib group.

Related Articles


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: